



Pharma Mar Group Reports 1H 2016 Financial Results

- **Reports total group net sales of €88.6 million (+6.5%)**
- **Net sales of Yondelis[®] increased by 5% to €45.7 million, while commercial sales rose by 10%**
- **Consumer Chemicals net sales increased by 7.4% to €39.3 million**

Madrid, July 26th, 2016: Pharma Mar Group (MSE:PHM) today announced its financial and corporate results for the first half of 2016. The Pharma Mar Group reported €88.6 million in total net sales in the first half of 2016, a 6.5% increase year-on-year. Sales increased in all the group's business lines. Net sales of Yondelis[®] (including raw material) increased by 5% to €45.7 million, while commercial sales increased by 10% with respect to the first half of 2015. Following approval of Yondelis for commercialization in the US and Japan last year, royalty revenues in the first half amounted to €3.1 million. Net sales in the Consumer Chemicals division increased by 7.4% in the first half of 2016, to €39.3 million.

With additional clinical trials, R&D spending increased by 27% to €38.7 million. Oncology R&D accounted for €35 million. The advanced status of the product pipeline, with several Phase III trials under way or about to commence, requires that the sizeable R&D expenditure of previous quarters be maintained. Growth in R&D spending is a major contributing factor to why Group EBITDA was negative in the first half of 2016 (-€5.6 million), contrasting with €9.4 million in the same period of 2015, when the Group also collected €10.2 million in licensing fees and other items that did not recur in 2016.

As a result, the Group reported a net attributable loss of -€13.2 million in the first half of 2016, compared with €3.3 million net profit in the same period of 2015.



About PharmaMar

PharmaMar, a Madrid-based biopharmaceutical company, is a world leader in discovering, developing and marketing anti-tumour drugs obtained from the sea. PharmaMar has a rich pipeline of pre-clinical candidates and a major R&D programme. The company develops and markets YONDELIS® in Europe and has three other compounds in clinical development for treating solid and haematological tumours: plitidepsin, PM1183 and PM184. PharmaMar is a global biopharmaceutical company with a presence in Germany, Italy, France, Switzerland, the United Kingdom, Belgium and the USA. PharmaMar also has a majority stake in other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, focused on developing therapeutic applications of gene silencing (RNAi); and two chemical companies: Zelnova Zeltia and Xylazel. For more information, visit our website: www.pharmamar.com

Important note

This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe for shares of the company. Moreover, no reliance should be placed upon this document or its distribution for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the Company.

Further information from:

Communication:

Paula Fernández – Media Relations Manager
pfalarcon@pharmamar.com
Mobile: +34 638796215
Phone: +34 918466000



Investor relations:

José Luis Moreno Martínez-Losa – Head of Investor Relations and Capital Markets
investorrelations@pharmamar.com
Phone: +34 914444500
For more information, visit our website: www.pharmamar.com

###